Scarica l'app Stockscreener
38.83
0.23%
-0.09
Dopo l'orario di chiusura:
38.83
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRMY Giù?
Forum
Previsione
Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie
Harmony Biosciences Holdings Inc Stock Analysis and ForecastVolatility Index Analysis & We Spotted the Next Tesla – See Inside - earlytimes.in
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG - Investing News Network
Harmony Biosciences partners with Beacon for EEG data in sleep trials By Investing.com - Investing.com South Africa
Harmony Biosciences partners with Beacon for EEG data in sleep trials - Investing.com Australia
Beacon Biosignals announces partnership with Harmony Biosciences - marketscreener.com
Nomura Holdings Inc. Raises Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Federated Hermes Inc. Reduces Stock Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Shows Niche Pharma Momentum Nasdaq Today - Kalkine Media
What analysts say about Harmony Biosciences Holdings Inc stockAutomated Trading Signals & Missed Nvidia? Don’t Miss This One - earlytimes.in
Harmony Advances Pitolisant GR After Bioequivalence Success - Sleep Review
Harmony Biosciences Prepares to Court Investors at Key December Healthcare Conferences - MSN
Harmony Biosciences (HRMY) Shares Promising Phase 3 Trial Results for EPX-100 - GuruFocus
Harmony Biosciences reports positive data for Dravet syndrome drug By Investing.com - Investing.com South Africa
Harmony Biosciences shows seizure reduction in dravet syndrome trial - StreetInsider
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome - Business Wire
Marshall Wace LLP Increases Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony’s Next-Gen Narcolepsy Drug Advances With Surprising New Results - MyChesCo
Arrowstreet Capital Limited Partnership Grows Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Capital Fund Management S.A. Invests $1.14 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
How supply chain issues affect Harmony Biosciences Holdings Inc. stockDividend Hike & Smart Allocation Stock Reports - Newser
How analysts rate Harmony Biosciences Holdings Inc. stock today2025 Trading Recap & Fast Exit and Entry Strategy Plans - Newser
Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo Finance
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data By Investing.com - Investing.com South Africa
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data - Investing.com Nigeria
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Biosciences to present Dravet syndrome trial data at AES meeting - Investing.com Canada
Harmony Biosciences Valuation Outlook After Recent Share Price Rebound - Yahoo Finance
How Pitolisant GR Progress and New Orexin Agonist Will Impact Harmony Biosciences (HRMY) Investors - Yahoo Finance
Harmony Biosciences (HRMY): Reassessing Valuation After Positive Pitolisant Study and New Orexin 2 Agonist Trial - Yahoo Finance
A Look at Harmony Biosciences (HRMY) Valuation Following Key Pipeline Advancements and Positive Trial Results - simplywall.st
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting - Business Wire
Harmony Biosciences to present Dravet syndrome trial data at AES meeting By Investing.com - Investing.com South Africa
Harmony Biosciences (Nasdaq: HRMY) to share new EPX-100 Dravet data at 2025 AES - Stock Titan
Prudential Financial Inc. Has $4.79 Million Stake in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Mizuho Maintains Harmony Biosciences Holdings (HRMY) Outperform Recommendation - Nasdaq
Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress By Investing.com - Investing.com South Africa
Harmony Biosciences Launches Early Trial of Promising Orexin Agonist - MSN
Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress - Investing.com Australia
HRMY Upgraded by Mizuho: Price Target Raised to $46 | HRMY Stock News - GuruFocus
Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating - marketscreener.com
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $46 at Mizuho - StreetInsider
Harmony Biosciences appoints Adam Zaeske as Chief Commercial Officer - MSN
0.39%
1.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):